GotoPER - Physicians' Education Resource
Back to Home
Video

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies, Combinations, and Clinical Trials Across MPN Care in the Context of Current Treatment Algorithms?

Create AccountAlready Registered? Login Here

Release Date

December 22, 2023

Expiration Date

December 23, 2024

Credits

2.5 CME, NCPD

Specialties

General Oncology, Hematology

Release Date: December 22, 2023

Expiration Date: December 22, 2024

Activity Overview

As the treatment options for myeloproliferative neoplasms (MPNs) rapidly expand with novel agents that aim to address previously unmet needs, health care professionals have large volumes of data to examine. Evaluation of this information is necessary for translating new evidence into best practices that have the potential to improve quality of life and survival in patients with MPNs. In this activity, the latest clinical trial data on the management of myelofibrosis, polycythemia vera, and essential thrombocytopenia will be presented along with a detailed discussion of challenging cases. Faculty will provide their perspectives on the management of these diseases, as well as look forward to the presentation of key data that may shift the future treatment landscape.

This educational activity is an archive of the live presentation held on December 8, 2023

Target Audience

This educational activity is directed toward medical oncologists, hematologic oncologists, hematologists, pharmacists, NP/PAs, nurses, and other health care professionals involved in the treatment of MPNs.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Devise treatment strategies to personalize care of patients with MPN based on genetics, risk stratification, and symptom burden
  • Discuss the efficacy and safety of current as well as emerging strategies in the management of patients with MPN across the disease continuum
  • Determine the impact of recent approvals, emerging data, and ongoing trials on the evolving algorithms for the management of patients with MPN across lines of care
  • Optimize care for patients with MPN by differentiating and managing symptoms as a result of disease progression from treatment-related adverse events
Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies, Combinations, and Clinical Trials Across MPN Care in the Context of Current Treatment Algorithms?

GET STARTED WITH THIS PROGRAM:

Register now to gain access to this program.

Create AccountAlready Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Geron Corporation; Incyte Corporation; and Protagonist Therapeutics.

Related Content

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology SocietyFree CE/CME

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Nevada Oncology SocietyFree CE/CME

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Nevada Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology SocietyFree CE/CME

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice SocietyFree CE/CME

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice Society

Course

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies, Combinations, and Clinical Trials Across MPN Care in the Context of Current Treatment Algorithms?

Create Account